重新评估73个全球疫苗免疫联盟国家轮状病毒疫苗接种的潜在影响与成本效果:一项模型研究
该模型研究评估了73个全球疫苗免疫联盟(Gavi)国家连续10个出生队列接种轮状病毒疫苗的成本与效果,发现2018-27年接种可预防近60万死亡,并在多数国家具有成本效果。
要点
- 2018-27年轮状病毒疫苗接种在Gavi国家可预防近60万死亡。
- 在54个国家,每避免一个伤残调整生命年的贴现成本有>90%概率低于人均GDP的0.5倍;在63个国家低于1.0倍。
核心结论
- 尽管轮状病毒死亡率估计降低且支付意愿阈值更严格,轮状病毒疫苗接种在大多数Gavi国家仍具有良好成本效果。
研究设计与样本
- 采用确定性队列模型,计算73个过去和当前符合Gavi支持资格国家连续10个出生队列在接种与不接种轮状病毒疫苗情况下的轮状病毒胃肠炎病例、门诊就诊、住院和死亡数。
- 从政府和社会视角计算治疗成本,主要结局为增量成本效果比(每避免一个伤残调整生命年的贴现美元),并进行了确定性和概率不确定性分析。
主要发现
- 2018-27年期间,轮状病毒疫苗接种在Gavi国家有潜力预防近60万死亡。
- 每避免一个伤残调整生命年的贴现成本有很高概率(>90%)在54个国家低于人均GDP的0.5倍,在63个国家低于人均GDP的1.0倍。
关键数值与推荐
- 主要结局指标为增量成本效果比(每避免一个伤残调整生命年的贴现美元)。
- 成本效果阈值评估:贴现美元/伤残调整生命年避免 <0.5倍人均GDP在54个国家概率>90%;<1.0倍人均GDP在63个国家概率>90%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous studies have found rotavirus vaccination to be highly cost-effective in low-income countries. However, updated evidence is now available for several inputs (ie, rotavirus disease mortality rates, rotavirus age distributions, vaccine timeliness, and vaccine efficacy by duration of follow-up), new rotavirus vaccines have entered the market, vaccine prices have decreased, and cost-effectiveness thresholds have been re-examined. We aimed to provide updated cost-effectiveness estimates to inform national decisions about the new introduction and current use of rotavirus vaccines in Gavi countries. METHODS: We calculated the potential costs and effects of rotavirus vaccination for ten successive birth cohorts in 73 countries previously and currently eligible for Gavi support, compared with no vaccination. We used a deterministic cohort model to calculate numbers of rotavirus gastroenteritis cases, outpatient visits, hospitalisations, and deaths between birth and 5 years, with and without rotavirus vaccination. We calculated treatment costs from the government and societal perspectives. The primary outcome measure was the incremental cost-effectiveness ratio (discounted US$ per disability-adjusted life-year averted). Country-specific model input parameters were based on the scientific literature, published meta-analyses, and international databases. We ran deterministic and probabilistic uncertainty analyses. FINDINGS: Over the period 2018-27, rotavirus vaccination has the potential to prevent nearly 600 000 deaths in Gavi countries. Averted outpatient visits and hospitalisations could lead to treatment savings of approximately $484·1 million from the government perspective and $878·0 million from the societal perspective. The discounted dollars per disability-adjusted life-year averted has a very high probability (>90%) of being less than 0·5 times the gross domestic product per capita in 54 countries, and less than 1·0 times gross domestic product per capita in 63 countries. INTERPRETATION: Rotavirus vaccination continues to represent good value for money across most Gavi countries despite lower rotavirus mortality estimates and more stringent willingness-to-pay thresholds. FUNDING: Bill & Melinda Gates Foundation.
引用
- Debellut F, Clark A, Pecenka C, et al. Re-evaluating the potential impact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries: a modelling study. Lancet Glob Health. 2019. PMID: 31708147. doi:10.1016/S2214-109X(19)30439-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。